Quote:

---

All this discussion of trial costs is pointless as the overwhelming likelihood is we will be partnering or selling at least one of our assets in the next 3-12 months. Indulging it is foolishness as it won't matter soon.

But just to indulge it a little...who cares if the trial costs $10M or $15M or $30M or $45M? The resulting dilution, assuming successful drugs, might affect whether we make it to $50 instead of $60 or $70 or $100. It doesn't impact whether one should be in this stock now. It's not going to impact whether we make it to $10 or even $20. The first 10-bagger is all on the science.

---